Dendreon appoints John Johnson to aid recovery
This article was originally published in Scrip
Executive Summary
Following Dendreon's recent share price crash (scripintelligence.com, 4 August 2011), the company has appointed John Johnson, CEO of Savient Pharmaceuticals, to its board of directors. Mr Johnson’s earlier corporate history saw him serve as CEO of Imclone during a period of global growth before Lilly acquired the company for $6.5 billion.